Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANXV in Recent Retinal Vein Occlusion
NCT05532735Phase 2Completed
- Sponsor
- Annexin Pharmaceuticals AB
- Start
- Aug 2022
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of annexin a5 in retinal vein occlusion (RVO), sponsored by Annexin Pharmaceuticals AB. Started Aug 2022; status: completed.
02
Drugs
annexin a5
03
Conditions
retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT05532735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05532735.